Literature DB >> 2122958

In vitro immunosuppressive and anti-phagocytic properties of the exopolysaccharide of mucoid strains of Pseudomonas aeruginosa.

G T Mai1, W K Seow, J G McCormack, Y H Thong.   

Abstract

The exopolysaccharide (EPS) of Pseudomonas aeruginosa was found to significantly inhibit neutrophil random movement, chemotaxis and degranulation at concentrations as low as 0.3 microgram/ml. Neutrophil adherence, respiratory burst and bactericidal capacity were inhibited by EPS concentrations of greater than or equal to 3 micrograms/ml. Similarly, mitogen-induced lymphocyte transformation was more sensitive to the inhibitory effects of EPS than natural-killer cell cytotoxicity. These results cannot be explained by simple mechanical blockade, as additions of EPS as late as 48 h after the initiation of lymphocyte cultures still resulted in a significant inhibition of lymphocyte transformation. However, the inhibitory effects of EPS can be reversed by extensive washing of treated lymphocytes. These results suggest that the propensity of mucoid P. aeruginosa to persist in cystic fibrosis may be explained in part by the ability of EPS to interfere with host immunity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2122958     DOI: 10.1159/000235199

Source DB:  PubMed          Journal:  Int Arch Allergy Appl Immunol        ISSN: 0020-5915


  3 in total

1.  Solution structure and properties of AlgH from Pseudomonas aeruginosa.

Authors:  Jeffrey L Urbauer; Aaron B Cowley; Hayley P Broussard; Henry T Niedermaier; Ramona J Bieber Urbauer
Journal:  Proteins       Date:  2015-04-29

2.  Inhibition of adherence of mucoid Pseudomonas aeruginosa by alginase, specific monoclonal antibodies, and antibiotics.

Authors:  G T Mai; J G McCormack; W K Seow; G B Pier; L A Jackson; Y H Thong
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

3.  Suppression of lymphocyte and neutrophil functions by Pseudomonas aeruginosa mucoid exopolysaccharide (alginate): reversal by physicochemical, alginase, and specific monoclonal antibody treatments.

Authors:  G T Mai; W K Seow; G B Pier; J G McCormack; Y H Thong
Journal:  Infect Immun       Date:  1993-02       Impact factor: 3.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.